{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:15:05Z","timestamp":1784632505034,"version":"3.55.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T00:00:00Z","timestamp":1247702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s12640-009-9070-9","type":"journal-article","created":{"date-parts":[[2009,7,20]],"date-time":"2009-07-20T17:10:52Z","timestamp":1248109852000},"page":"15-27","source":"Crossref","is-referenced-by-count":64,"title":["Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30"],"prefix":"10.1007","volume":"17","author":[{"given":"Shunit","family":"Gal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mati","family":"Fridkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa B. H.","family":"Youdim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,16]]},"reference":[{"key":"9070_CR1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1471-4159.2002.01047.x","volume":"82","author":"Y Akao","year":"2002","unstructured":"Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82:913\u2013923","journal-title":"J Neurochem"},{"key":"9070_CR2","doi-asserted-by":"crossref","unstructured":"Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S (2007) Targeting multiple Alzheimer\u2019s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. Faseb J","DOI":"10.1096\/fj.07-8627rev"},{"key":"9070_CR3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1471-4159.2006.04258.x","volume":"100","author":"Y Avramovich-Tirosh","year":"2007","unstructured":"Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB (2007) Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer\u2019s disease. J Neurochem 100:490\u2013502","journal-title":"J Neurochem"},{"key":"9070_CR4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1471-4159.2004.02425.x","volume":"89","author":"O Bar-Am","year":"2004","unstructured":"Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MBH (2004) Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 89:1119\u20131125","journal-title":"J Neurochem"},{"key":"9070_CR5","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1096\/fj.05-3794fje","volume":"19","author":"O Bar-Am","year":"2005","unstructured":"Bar-Am O, Weinreb O, Amit T, Youdim MB (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. Faseb J 19:1899\u20131901","journal-title":"Faseb J"},{"key":"9070_CR7","first-page":"251","volume":"29","author":"D Ben-Shachar","year":"1990","unstructured":"Ben-Shachar D, Youdim MBH (1990) Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson\u2019s disease may depend on iron-melanin interaction. J Neural Transm Suppl 29:251\u2013258","journal-title":"J Neural Transm Suppl"},{"key":"9070_CR6","doi-asserted-by":"crossref","unstructured":"Ben-Shachar D, Kahana N, Kampel V, Warshawsky A, Youdim MBH (2003) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology","DOI":"10.1016\/j.neuropharm.2003.09.005"},{"key":"9070_CR8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuropharm.2003.09.005","volume":"46","author":"D Ben-Shachar","year":"2004","unstructured":"Ben-Shachar D, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46:254\u2013263","journal-title":"Neuropharmacology"},{"key":"9070_CR9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/mds.20311","volume":"20","author":"D Berg","year":"2005","unstructured":"Berg D, Merz B, Reiners K, Naumann M, Becker G (2005) Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson\u2019s disease. Mov Disord 20:383\u2013385","journal-title":"Mov Disord"},{"key":"9070_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03033302","volume":"9","author":"D Berg","year":"2006","unstructured":"Berg D, Hochstrasser H, Schweitzer KJ, Riess O (2006) Disturbance of iron metabolism in Parkinson\u2019s disease\u2014ultrasonography as a biomarker. Neurotox Res 9:1\u201313","journal-title":"Neurotox Res"},{"key":"9070_CR11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res 318:121\u2013134","journal-title":"Cell Tissue Res"},{"key":"9070_CR12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0024-3205(00)00643-3","volume":"67","author":"MC Carrillo","year":"2000","unstructured":"Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MBH (2000) Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67:577\u2013585","journal-title":"Life Sci"},{"key":"9070_CR13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.7901908","volume":"262","author":"JT Coyle","year":"1993","unstructured":"Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689\u2013695","journal-title":"Science"},{"key":"9070_CR14","doi-asserted-by":"crossref","unstructured":"Faiz M, Acarin L, Castellano B, Gonzalez B (2005) Proliferation dynamics of germinative zone cells in the intact and excitotoxically lesioned postnatal rat brain. BMC Neurosci 6:26","DOI":"10.1186\/1471-2202-6-26"},{"key":"9070_CR15","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1523\/JNEUROSCI.23-26-08955.2003","volume":"23","author":"F Fornai","year":"2003","unstructured":"Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti CL, Ruffoli R, Soldani P, Ruggieri S, Alessandri MG, Paparelli A (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci 23:8955\u20138966","journal-title":"J Neurosci"},{"key":"9070_CR16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.mp.4001937","volume":"12","author":"AL Friedlich","year":"2007","unstructured":"Friedlich AL, Tanzi RE, Rogers JT (2007) The 5\u2032-untranslated region of Parkinson\u2019s disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol Psychiatry 12:222\u2013223","journal-title":"Mol Psychiatry"},{"key":"9070_CR17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1471-4159.2005.03341.x","volume":"95","author":"S Gal","year":"2005","unstructured":"Gal S, Zheng H, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95:79\u201388","journal-title":"J Neurochem"},{"key":"9070_CR18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/978-3-211-45295-0_68","volume":"70","author":"S Gal","year":"2006","unstructured":"Gal S, Fridkin M, Amit T, Zheng H, Youdim MB (2006) M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson\u2019s disease. J Neural Transm Suppl 70:447\u2013456","journal-title":"J Neural Transm Suppl"},{"key":"9070_CR19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0028-3908(01)00019-3","volume":"40","author":"Y Gilgun-Sherki","year":"2001","unstructured":"Gilgun-Sherki Y, Melamed E, Offen D (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40:959\u2013975","journal-title":"Neuropharmacology"},{"key":"9070_CR20","first-page":"329","volume":"292","author":"YY Glinka","year":"1995","unstructured":"Glinka YY, Youdim MB (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol 292:329\u2013332","journal-title":"Eur J Pharmacol"},{"key":"9070_CR21","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1046\/j.1471-4159.1996.66052004.x","volume":"66","author":"Y Glinka","year":"1996","unstructured":"Glinka Y, Tipton KF, Youdim MB (1996) Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem 66:2004\u20132010","journal-title":"J Neurochem"},{"key":"9070_CR22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(98)00279-9","volume":"351","author":"Y Glinka","year":"1998","unstructured":"Glinka Y, Tipton KF, Youdim MBH (1998) Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur J Pharmacol 351:121\u2013129","journal-title":"Eur J Pharmacol"},{"key":"9070_CR23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0006-8993(96)00284-3","volume":"724","author":"K Goto","year":"1996","unstructured":"Goto K, Mochizuki H, Imai H, Akiyama H, Mizuno Y (1996) An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Brain Res 724:125\u2013128","journal-title":"Brain Res"},{"key":"9070_CR24","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00702-004-0212-1","volume":"111","author":"E Grunblatt","year":"2004","unstructured":"Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MB (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion\/cellular matrix and vesicle trafficking genes. J Neural Transm 111:1543\u20131573","journal-title":"J Neural Transm"},{"key":"9070_CR25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0022-510X(92)90247-I","volume":"113","author":"S Hall","year":"1992","unstructured":"Hall S, Rutledge JN, Schallert T (1992) MRI, brain iron and experimental Parkinson\u2019s disease. J Neurol Sci 113:198\u2013208","journal-title":"J Neurol Sci"},{"key":"9070_CR26","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1046\/j.1471-4159.1999.731683.x","volume":"73","author":"J Han","year":"1999","unstructured":"Han J, Cheng FC, Yang Z, Dryhurst G (1999) Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson\u2019s disease. J Neurochem 73:1683\u20131695","journal-title":"J Neurochem"},{"key":"9070_CR27","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1523\/JNEUROSCI.4564-03.2004","volume":"24","author":"S Hayley","year":"2004","unstructured":"Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS (2004) Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson\u2019s disease. J Neurosci 24:2045\u20132053","journal-title":"J Neurosci"},{"key":"9070_CR28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrn2124","volume":"8","author":"K Herrup","year":"2007","unstructured":"Herrup K, Yang Y (2007) Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat Rev Neurosci 8:368\u2013378","journal-title":"Nat Rev Neurosci"},{"key":"9070_CR29","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1038\/sj.onc.1208527","volume":"24","author":"Y Huang","year":"2005","unstructured":"Huang Y, Wernyj RP, Norton DD, Precht P, Seminario MC, Wange RL (2005) Modulation of specific protein expression levels by PTEN: identification of AKAP121, DHFR, G3BP, Rap1, and RCC1 as potential targets of PTEN. Oncogene 24:3819\u20133829","journal-title":"Oncogene"},{"key":"9070_CR30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0896-6273(03)00126-0","volume":"37","author":"D Kaur","year":"2003","unstructured":"Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson\u2019s disease. Neuron 37:899\u2013909","journal-title":"Neuron"},{"key":"9070_CR31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000017427","volume":"22","author":"JN Kay","year":"2000","unstructured":"Kay JN, Blum M (2000) Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection. Dev Neurosci 22:56\u201367","journal-title":"Dev Neurosci"},{"key":"9070_CR32","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.npp.1300924","volume":"31","author":"G Keilhoff","year":"2006","unstructured":"Keilhoff G, Becker A, Grecksch G, Bernstein HG, Wolf G (2006) Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropsychopharmacology 31:1165\u20131176","journal-title":"Neuropsychopharmacology"},{"key":"9070_CR33","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1523\/JNEUROSCI.19-06-02337.1999","volume":"19","author":"B Kolb","year":"1999","unstructured":"Kolb B, Pedersen B, Ballermann M, Gibb R, Whishaw IQ (1999) Embryonic and postnatal injections of bromodeoxyuridine produce age-dependent morphological and behavioral abnormalities. J Neurosci 19:2337\u20132346","journal-title":"J Neurosci"},{"key":"9070_CR101","doi-asserted-by":"crossref","unstructured":"Kupershmidt L, Weinreb O, Mandel S, Amit T, Youdim MBH (2009) Involvement of HIF and VGEF in neuroprotective and neuritogenic activities of novel multimodal iron chelating drugs in motor neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J (in press)","DOI":"10.1096\/fj.09-130047"},{"key":"9070_CR34","doi-asserted-by":"crossref","first-page":"12623","DOI":"10.1523\/JNEUROSCI.3812-07.2007","volume":"27","author":"DC Lagace","year":"2007","unstructured":"Lagace DC, Whitman MC, Noonan MA, Ables JL, DeCarolis NA, Arguello AA, Donovan MH, Fischer SJ, Farnbauch LA, Beech RD, DiLeone RJ, Greer CA, Mandyam CD, Eisch AJ (2007) Dynamic contribution of nestin-expressing stem cells to adult neurogenesis. J Neurosci 27:12623\u201312629","journal-title":"J Neurosci"},{"key":"9070_CR35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF01277665","volume":"104","author":"J Lan","year":"1997","unstructured":"Lan J, Jiang DH (1997a) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104:469\u2013481","journal-title":"J Neural Transm"},{"key":"9070_CR36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/BF01291883","volume":"104","author":"J Lan","year":"1997","unstructured":"Lan J, Jiang DH (1997b) Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson\u2019s disease. J Neural Transm 104:649\u2013660","journal-title":"J Neural Transm"},{"key":"9070_CR37","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1046\/j.1471-4159.2001.00490.x","volume":"78","author":"Y Levites","year":"2001","unstructured":"Levites Y, Weinreb O, Maor G, Youdim MBH, Mandel S (2001) Green tea polyphenol (-)-Epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78:1073\u20131082","journal-title":"J Neurochem"},{"key":"9070_CR38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1124\/mol.52.3.465","volume":"52","author":"YL Lin","year":"1997","unstructured":"Lin YL, Lin JK (1997) (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol 52:465\u2013472","journal-title":"Mol Pharmacol"},{"key":"9070_CR39","first-page":"G1355","volume":"272","author":"M Lin","year":"1997","unstructured":"Lin M, Rippe RA, Niemela O, Brittenham G, Tsukamoto H (1997) Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Physiol 272:G1355\u2013G1364","journal-title":"Am J Physiol"},{"key":"9070_CR40","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00023210-200317100-00004","volume":"17","author":"S Mandel","year":"2003","unstructured":"Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB (2003) Neuroprotective strategies in Parkinson\u2019s disease: an update on progress. CNS Drugs 17:729\u2013762","journal-title":"CNS Drugs"},{"key":"9070_CR41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1749-6632.2001.tb03641.x","volume":"939","author":"W Maruyama","year":"2001","unstructured":"Maruyama W, Youdim MBH, Naoi M (2001a) Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci 939:320\u2013329","journal-title":"Ann N Y Acad Sci"},{"key":"9070_CR42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1046\/j.1471-4159.2001.00448.x","volume":"78","author":"W Maruyama","year":"2001","unstructured":"Maruyama W, Akao Y, Youdim MBH, Boulton AA, Davis BA, Naoi M (2001b) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78:727\u2013735","journal-title":"J Neurochem"},{"key":"9070_CR43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s007020200038","volume":"109","author":"W Maruyama","year":"2002","unstructured":"Maruyama W, Takahashi T, Youdim MBH, Naoi M (2002) The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109:467\u2013481","journal-title":"J Neural Transm"},{"key":"9070_CR44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neuint.2003.08.005","volume":"44","author":"W Maruyama","year":"2004","unstructured":"Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim MBH, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 44:393\u2013400","journal-title":"Neurochem Int"},{"key":"9070_CR45","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.neurobiolaging.2005.08.012","volume":"27","author":"KS McNaught","year":"2006","unstructured":"McNaught KS, Olanow CW (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson\u2019s disease. Neurobiol Aging 27:530\u2013545","journal-title":"Neurobiol Aging"},{"key":"9070_CR46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0304-3940(94)90462-6","volume":"168","author":"H Mochizuki","year":"1994","unstructured":"Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, Hattori N, Mizuno Y (1994) Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett 168:251\u2013253","journal-title":"Neurosci Lett"},{"key":"9070_CR47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jnnp.64.3.314","volume":"64","author":"PK Morrish","year":"1998","unstructured":"Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson\u2019s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64:314\u2013319","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9070_CR48","doi-asserted-by":"crossref","unstructured":"Munoz M, Rodriguez A, Diez C, Caamano JN, Fernandez-Sanchez MT, Perez-Gomez A, De Frutos C, Facal N, Gomez E (2009) Tyrosine kinase A, C and fibroblast growth factor-2 receptors in bovine embryos cultured in vitro. Theriogenology 71(6):1005\u20131010","DOI":"10.1016\/j.theriogenology.2008.11.008"},{"key":"9070_CR49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0006-8993(94)90833-8","volume":"660","author":"E Oestreicher","year":"1994","unstructured":"Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660:8\u201318","journal-title":"Brain Res."},{"key":"9070_CR50","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1073\/pnas.95.10.5789","volume":"95","author":"D Offen","year":"1998","unstructured":"Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O (1998) Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA 95:5789\u20135794","journal-title":"Proc Natl Acad Sci USA"},{"key":"9070_CR51","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1523\/JNEUROSCI.20-16-06048.2000","volume":"20","author":"N Ostrerova-Golts","year":"2000","unstructured":"Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20:6048\u20136054","journal-title":"J Neurosci"},{"key":"9070_CR52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.neuroscience.2008.02.063","volume":"153","author":"J Peng","year":"2008","unstructured":"Peng J, Xie L, Jin K, Greenberg DA, Andersen JK (2008) Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson\u2019s disease. Neuroscience 153:664\u2013670","journal-title":"Neuroscience"},{"key":"9070_CR53","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1073\/pnas.0609874104","volume":"104","author":"C Perier","year":"2007","unstructured":"Perier C, Bove J, Wu DC, Dehay B, Choi DK, Jackson-Lewis V, Rathke-Hartlieb S, Bouillet P, Strasser A, Schulz JB, Przedborski S, Vila M (2007) Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson\u2019s disease. Proc Natl Acad Sci USA 104:8161\u20138166","journal-title":"Proc Natl Acad Sci USA"},{"key":"9070_CR54","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0003-9861(87)90531-5","volume":"259","author":"RR Ramsay","year":"1987","unstructured":"Ramsay RR, Kowal AT, Johnson MK, Salach JI, Singer TP (1987) The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch Biochem Biophys 259:645\u2013649","journal-title":"Arch Biochem Biophys"},{"key":"9070_CR55","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1046\/j.1471-4159.2003.01801.x","volume":"2","author":"Y Sagi","year":"2003","unstructured":"Sagi Y, Weinstock M, Youdim MBH (2003) Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 2:290\u2013297","journal-title":"J Neurochem"},{"key":"9070_CR56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nbd.2006.07.020","volume":"25","author":"Y Sagi","year":"2007","unstructured":"Sagi Y, Mandel S, Amit T, Youdim MB (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25:35\u201344","journal-title":"Neurobiol Dis"},{"key":"9070_CR57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000065700","volume":"24","author":"P Sangchot","year":"2002","unstructured":"Sangchot P, Sharma S, Chetsawang B, Porter J, Govitrapong P, Ebadi M (2002) Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev Neurosci 24:143\u2013153","journal-title":"Dev Neurosci"},{"key":"9070_CR58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(96)00593-6","volume":"315","author":"I Semkova","year":"1996","unstructured":"Semkova I, Wolz P, Schilling M, Krieglstein J (1996) Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol 315:19\u201330","journal-title":"Eur J Pharmacol"},{"key":"9070_CR59","doi-asserted-by":"crossref","first-page":"41732","DOI":"10.1074\/jbc.M504963200","volume":"280","author":"A Siddiq","year":"2005","unstructured":"Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, Ratan RR (2005) Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 280:41732\u201341743","journal-title":"J Biol Chem"},{"key":"9070_CR60","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1124\/jpet.301.2.753","volume":"301","author":"WG Tatton","year":"2002","unstructured":"Tatton WG, Chalmers-Redman RM, Ju WJ, Mammen M, Carlile GW, Pong AW, Tatton NA (2002) Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301:753\u2013764","journal-title":"J Pharmacol Exp Ther"},{"key":"9070_CR61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1471-4159.1994.62010134.x","volume":"62","author":"JA Temlett","year":"1994","unstructured":"Temlett JA, Landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 62:134\u2013146","journal-title":"J Neurochem"},{"key":"9070_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-540-39617-8_1","volume":"191","author":"AB Tonchev","year":"2007","unstructured":"Tonchev AB, Yamashima T, Chaldakov GN (2007) Distribution and phenotype of proliferating cells in the forebrain of adult macaque monkeys after transient global cerebral ischemia. Adv Anat Embryol Cell Biol 191:1\u2013106","journal-title":"Adv Anat Embryol Cell Biol"},{"key":"9070_CR63","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1523\/JNEUROSCI.0837-06.2006","volume":"26","author":"JM Kampen Van","year":"2006","unstructured":"Van Kampen JM, Eckman CB (2006) Dopamine D3 receptor agonist delivery to a model of Parkinson\u2019s disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 26:7272\u20137280","journal-title":"J Neurosci"},{"key":"9070_CR64","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1073\/pnas.051633998","volume":"98","author":"M Vila","year":"2001","unstructured":"Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Proc Natl Acad Sci USA 98:2837\u20132842","journal-title":"Proc Natl Acad Sci USA"},{"key":"9070_CR65","unstructured":"Warshawsky A, Youdim MB, Fridkin M, Zheng HL, Warshawsky R (2004) Preparation of neuroprotective iron chelators and pharmaceutical compositions comprising them. Int Publication Number WO 2004041151, A2"},{"key":"9070_CR66","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1096\/fj.04-1916fje","volume":"18","author":"O Weinreb","year":"2004","unstructured":"Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MB (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. Faseb J 18:1471\u20131473","journal-title":"Faseb J"},{"key":"9070_CR67","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/978-3-211-45295-0_69","volume":"70","author":"O Weinreb","year":"2006","unstructured":"Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S, Youdim MB (2006) Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl 70:457\u2013465","journal-title":"J Neural Transm Suppl"},{"key":"9070_CR68","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0278-5846(03)00053-8","volume":"27","author":"M Weinstock","year":"2003","unstructured":"Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim MBH (2003) A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson\u2019s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 27:555\u2013561","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"9070_CR69","doi-asserted-by":"crossref","first-page":"8145","DOI":"10.1523\/JNEUROSCI.18-20-08145.1998","volume":"18","author":"L Yang","year":"1998","unstructured":"Yang L, Matthews RT, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney J B Jr, Hyman BT, Beal MF (1998) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 18:8145\u20138152","journal-title":"J Neurosci"},{"key":"9070_CR70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.20506","volume":"58","author":"K Yoshimi","year":"2005","unstructured":"Yoshimi K, Ren YR, Seki T, Yamada M, Ooizumi H, Onodera M, Saito Y, Murayama S, Okano H, Mizuno Y, Mochizuki H (2005) Possibility for neurogenesis in substantia nigra of parkinsonian brain. Ann Neurol 58:31\u201340","journal-title":"Ann Neurol"},{"key":"9070_CR71","first-page":"737","volume":"3","author":"MBH Youdim","year":"2003","unstructured":"Youdim MBH (2003) Rasagiline: an anti-Parkinson drug with neuroprotective activity. Future Drugs 3:737\u2013749","journal-title":"Future Drugs"},{"key":"9070_CR72","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.2001.tb03656.x","volume":"939","author":"MBH Youdim","year":"2001","unstructured":"Youdim MBH, Wadia A, Tatton NA, Weinstock M (2001) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939:450\u2013458","journal-title":"Ann N Y Acad Sci"},{"key":"9070_CR73","doi-asserted-by":"crossref","unstructured":"Youdim MBH, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson\u2019s disease and other neurodegenerative diseases with iron chelator: a lesson from 6-hydroxopaime and iron chelatos desferal and VK-28. Ann N Y Acad Sci 1012:306\u2013325","DOI":"10.1196\/annals.1306.025"},{"key":"9070_CR74","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jnr.20350","volume":"79","author":"MB Youdim","year":"2005","unstructured":"Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2005) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79:172\u2013179","journal-title":"J Neurosci Res"},{"key":"9070_CR75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03033355","volume":"10","author":"MB Youdim","year":"2006","unstructured":"Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M (2006) Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotox Res 10:181\u2013192","journal-title":"Neurotox Res"},{"key":"9070_CR76","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00702-006-0499-1","volume":"114","author":"MB Youdim","year":"2007","unstructured":"Youdim MB, Grunblatt E, Mandel S (2007) The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. J Neural Transm 114:205\u2013209","journal-title":"J Neural Transm"},{"key":"9070_CR77","doi-asserted-by":"crossref","first-page":"9821","DOI":"10.1523\/JNEUROSCI.19-22-09821.1999","volume":"19","author":"K Zaman","year":"1999","unstructured":"Zaman K, Ryu H, Hall D, O\u2019Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, Ratan RR (1999) Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1\/CREB and increased expression of glycolytic enzymes, p21(waf1\/cip1), and erythropoietin. J Neurosci 19:9821\u20139830","journal-title":"J Neurosci"},{"key":"9070_CR78","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrn1537","volume":"5","author":"L Zecca","year":"2004","unstructured":"Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863\u2013873","journal-title":"Nat Rev Neurosci"},{"key":"9070_CR79","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/mds.20550","volume":"20","author":"L Zecca","year":"2005","unstructured":"Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M, Tampellini D, Riederer P, Gerlach M, Becker G (2005) In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 20:1278\u20131285","journal-title":"Mov Disord"},{"key":"9070_CR80","doi-asserted-by":"crossref","first-page":"7925","DOI":"10.1073\/pnas.1131955100","volume":"100","author":"M Zhao","year":"2003","unstructured":"Zhao M, Momma S, Delfani K, Carlen M, Cassidy RM, Johansson CB, Brismar H, Shupliakov O, Frisen J, Janson AM (2003) Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci USA 100:7925\u20137930","journal-title":"Proc Natl Acad Sci USA"},{"key":"9070_CR81","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1471-4159.2005.03340.x","volume":"95","author":"H Zheng","year":"2005","unstructured":"Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB (2005a) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95:68\u201378","journal-title":"J Neurochem"},{"key":"9070_CR82","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bmc.2004.10.037","volume":"13","author":"H Zheng","year":"2005","unstructured":"Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MBH, Fridkin M (2005b) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer\u2019s, Parkinson\u2019s, and other neurodegenerative diseases. Bioorg Med Chem 13:773\u2013783","journal-title":"Bioorg Med Chem"},{"key":"9070_CR83","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1096\/fj.07-8386com","volume":"21","author":"W Zhu","year":"2007","unstructured":"Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MB, Le W (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Faseb J 21:3835\u20133844","journal-title":"Faseb J"},{"key":"9070_CR84","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1111\/j.1471-4159.2008.05330.x","volume":"105","author":"W Zhu","year":"2008","unstructured":"Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, Le W (2008) Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 105:1970\u20131978","journal-title":"J Neurochem"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-009-9070-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12640-009-9070-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-009-9070-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T09:52:07Z","timestamp":1710496327000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12640-009-9070-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,16]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["9070"],"URL":"https:\/\/doi.org\/10.1007\/s12640-009-9070-9","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,16]]}}}